Leukocytoclastic vasculitis associated with capecitabine
Background Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoadjuvant capecitabine use for locally advanced recta...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice 2024-10, Vol.30 (7), p.1282-1286 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1286 |
|---|---|
| container_issue | 7 |
| container_start_page | 1282 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 30 |
| creator | Arici, Mustafa Ozgur Avsar, Esin Kilic, Ozlem Salim, Derya Kivrak |
| description | Background
Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoadjuvant capecitabine use for locally advanced rectal cancer (LARC).
Case report
A 70-year-old man presented with rectal bleeding. A colonoscopic biopsy revealed rectal adenocarcinoma and he was diagnosed with LARC after imaging studies. Capecitabine plus radiation therapy was started as a neoadjuvant treatment.
Management and outcome
Seven days after the first capecitabine dose, the patient was admitted with a rash. The LCV diagnosis was histopathologically proven. Capecitabine was withheld. After the patient's rash began to regress under corticosteroid pressure, capecitabine was started at a lower dose. His treatment was completed successfully with oral corticosteroids plus low-dose capecitabine.
Discussion
We aimed to point out a rare and unusual adverse effect of a frequently used drug in oncologic practice. |
| doi_str_mv | 10.1177/10781552231167812 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2797145438</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_10781552231167812</sage_id><sourcerecordid>2797145438</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-2d7601084ebf658972532f4cb0f63b0baf58009e51d685036e6a0a2d1fac796e3</originalsourceid><addsrcrecordid>eNp1kM1Lw0AQxRdRbK3-AV4k4MVL6sxu9iNHKfUDCl4UvIXNZqNb06ZmN0r_e7e0Kiie5sH83pvhEXKKMEaU8hJBKuScUoYooqR7ZIiZlCnk9Gk_6rhPN8CAHHk_BwAlqTokAyaBYiZgSNTM9q-tWYfWNNoHZ5J37U3fuOB8or1vjdPBVsmHCy-J0StrXNClW9pjclDrxtuT3RyRx-vpw-Q2nd3f3E2uZqlhQoWUVlIAgspsWQuuckk5o3VmSqgFK6HUNVcAueVYCcWBCSs0aFphrY3MhWUjcrHNXXXtW299KBbOG9s0emnb3hdU5hIznjEV0fNf6Lztu2X8rmBIs0jFW5HCLWW61vvO1sWqcwvdrQuEYlNr8afW6DnbJfflwlbfjq8eIzDeAl4_25-z_yd-AiAZffA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3124145580</pqid></control><display><type>article</type><title>Leukocytoclastic vasculitis associated with capecitabine</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Arici, Mustafa Ozgur ; Avsar, Esin ; Kilic, Ozlem ; Salim, Derya Kivrak</creator><creatorcontrib>Arici, Mustafa Ozgur ; Avsar, Esin ; Kilic, Ozlem ; Salim, Derya Kivrak</creatorcontrib><description>Background
Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoadjuvant capecitabine use for locally advanced rectal cancer (LARC).
Case report
A 70-year-old man presented with rectal bleeding. A colonoscopic biopsy revealed rectal adenocarcinoma and he was diagnosed with LARC after imaging studies. Capecitabine plus radiation therapy was started as a neoadjuvant treatment.
Management and outcome
Seven days after the first capecitabine dose, the patient was admitted with a rash. The LCV diagnosis was histopathologically proven. Capecitabine was withheld. After the patient's rash began to regress under corticosteroid pressure, capecitabine was started at a lower dose. His treatment was completed successfully with oral corticosteroids plus low-dose capecitabine.
Discussion
We aimed to point out a rare and unusual adverse effect of a frequently used drug in oncologic practice.</description><identifier>ISSN: 1078-1552</identifier><identifier>ISSN: 1477-092X</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/10781552231167812</identifier><identifier>PMID: 37021460</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adenocarcinoma ; Adenocarcinoma - drug therapy ; Aged ; Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Biopsy ; Blood vessels ; Capecitabine - adverse effects ; Capecitabine - therapeutic use ; Corticosteroids ; Exanthema ; Humans ; Male ; Neoadjuvant Therapy - adverse effects ; Radiation therapy ; Rectal Neoplasms - drug therapy ; Rectum ; Vasculitis ; Vasculitis, Leukocytoclastic, Cutaneous - chemically induced</subject><ispartof>Journal of oncology pharmacy practice, 2024-10, Vol.30 (7), p.1282-1286</ispartof><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-2d7601084ebf658972532f4cb0f63b0baf58009e51d685036e6a0a2d1fac796e3</citedby><cites>FETCH-LOGICAL-c368t-2d7601084ebf658972532f4cb0f63b0baf58009e51d685036e6a0a2d1fac796e3</cites><orcidid>0000-0003-4107-3460 ; 0000-0001-9821-6368</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/10781552231167812$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/10781552231167812$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37021460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arici, Mustafa Ozgur</creatorcontrib><creatorcontrib>Avsar, Esin</creatorcontrib><creatorcontrib>Kilic, Ozlem</creatorcontrib><creatorcontrib>Salim, Derya Kivrak</creatorcontrib><title>Leukocytoclastic vasculitis associated with capecitabine</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Background
Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoadjuvant capecitabine use for locally advanced rectal cancer (LARC).
Case report
A 70-year-old man presented with rectal bleeding. A colonoscopic biopsy revealed rectal adenocarcinoma and he was diagnosed with LARC after imaging studies. Capecitabine plus radiation therapy was started as a neoadjuvant treatment.
Management and outcome
Seven days after the first capecitabine dose, the patient was admitted with a rash. The LCV diagnosis was histopathologically proven. Capecitabine was withheld. After the patient's rash began to regress under corticosteroid pressure, capecitabine was started at a lower dose. His treatment was completed successfully with oral corticosteroids plus low-dose capecitabine.
Discussion
We aimed to point out a rare and unusual adverse effect of a frequently used drug in oncologic practice.</description><subject>Adenocarcinoma</subject><subject>Adenocarcinoma - drug therapy</subject><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Biopsy</subject><subject>Blood vessels</subject><subject>Capecitabine - adverse effects</subject><subject>Capecitabine - therapeutic use</subject><subject>Corticosteroids</subject><subject>Exanthema</subject><subject>Humans</subject><subject>Male</subject><subject>Neoadjuvant Therapy - adverse effects</subject><subject>Radiation therapy</subject><subject>Rectal Neoplasms - drug therapy</subject><subject>Rectum</subject><subject>Vasculitis</subject><subject>Vasculitis, Leukocytoclastic, Cutaneous - chemically induced</subject><issn>1078-1552</issn><issn>1477-092X</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1Lw0AQxRdRbK3-AV4k4MVL6sxu9iNHKfUDCl4UvIXNZqNb06ZmN0r_e7e0Kiie5sH83pvhEXKKMEaU8hJBKuScUoYooqR7ZIiZlCnk9Gk_6rhPN8CAHHk_BwAlqTokAyaBYiZgSNTM9q-tWYfWNNoHZ5J37U3fuOB8or1vjdPBVsmHCy-J0StrXNClW9pjclDrxtuT3RyRx-vpw-Q2nd3f3E2uZqlhQoWUVlIAgspsWQuuckk5o3VmSqgFK6HUNVcAueVYCcWBCSs0aFphrY3MhWUjcrHNXXXtW299KBbOG9s0emnb3hdU5hIznjEV0fNf6Lztu2X8rmBIs0jFW5HCLWW61vvO1sWqcwvdrQuEYlNr8afW6DnbJfflwlbfjq8eIzDeAl4_25-z_yd-AiAZffA</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Arici, Mustafa Ozgur</creator><creator>Avsar, Esin</creator><creator>Kilic, Ozlem</creator><creator>Salim, Derya Kivrak</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4107-3460</orcidid><orcidid>https://orcid.org/0000-0001-9821-6368</orcidid></search><sort><creationdate>20241001</creationdate><title>Leukocytoclastic vasculitis associated with capecitabine</title><author>Arici, Mustafa Ozgur ; Avsar, Esin ; Kilic, Ozlem ; Salim, Derya Kivrak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-2d7601084ebf658972532f4cb0f63b0baf58009e51d685036e6a0a2d1fac796e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adenocarcinoma</topic><topic>Adenocarcinoma - drug therapy</topic><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Biopsy</topic><topic>Blood vessels</topic><topic>Capecitabine - adverse effects</topic><topic>Capecitabine - therapeutic use</topic><topic>Corticosteroids</topic><topic>Exanthema</topic><topic>Humans</topic><topic>Male</topic><topic>Neoadjuvant Therapy - adverse effects</topic><topic>Radiation therapy</topic><topic>Rectal Neoplasms - drug therapy</topic><topic>Rectum</topic><topic>Vasculitis</topic><topic>Vasculitis, Leukocytoclastic, Cutaneous - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arici, Mustafa Ozgur</creatorcontrib><creatorcontrib>Avsar, Esin</creatorcontrib><creatorcontrib>Kilic, Ozlem</creatorcontrib><creatorcontrib>Salim, Derya Kivrak</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arici, Mustafa Ozgur</au><au>Avsar, Esin</au><au>Kilic, Ozlem</au><au>Salim, Derya Kivrak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Leukocytoclastic vasculitis associated with capecitabine</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>30</volume><issue>7</issue><spage>1282</spage><epage>1286</epage><pages>1282-1286</pages><issn>1078-1552</issn><issn>1477-092X</issn><eissn>1477-092X</eissn><abstract>Background
Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoadjuvant capecitabine use for locally advanced rectal cancer (LARC).
Case report
A 70-year-old man presented with rectal bleeding. A colonoscopic biopsy revealed rectal adenocarcinoma and he was diagnosed with LARC after imaging studies. Capecitabine plus radiation therapy was started as a neoadjuvant treatment.
Management and outcome
Seven days after the first capecitabine dose, the patient was admitted with a rash. The LCV diagnosis was histopathologically proven. Capecitabine was withheld. After the patient's rash began to regress under corticosteroid pressure, capecitabine was started at a lower dose. His treatment was completed successfully with oral corticosteroids plus low-dose capecitabine.
Discussion
We aimed to point out a rare and unusual adverse effect of a frequently used drug in oncologic practice.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>37021460</pmid><doi>10.1177/10781552231167812</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-4107-3460</orcidid><orcidid>https://orcid.org/0000-0001-9821-6368</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2024-10, Vol.30 (7), p.1282-1286 |
| issn | 1078-1552 1477-092X 1477-092X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2797145438 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adenocarcinoma Adenocarcinoma - drug therapy Aged Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Biopsy Blood vessels Capecitabine - adverse effects Capecitabine - therapeutic use Corticosteroids Exanthema Humans Male Neoadjuvant Therapy - adverse effects Radiation therapy Rectal Neoplasms - drug therapy Rectum Vasculitis Vasculitis, Leukocytoclastic, Cutaneous - chemically induced |
| title | Leukocytoclastic vasculitis associated with capecitabine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A30%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Leukocytoclastic%20vasculitis%20associated%20with%20capecitabine&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Arici,%20Mustafa%20Ozgur&rft.date=2024-10-01&rft.volume=30&rft.issue=7&rft.spage=1282&rft.epage=1286&rft.pages=1282-1286&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/10781552231167812&rft_dat=%3Cproquest_cross%3E2797145438%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3124145580&rft_id=info:pmid/37021460&rft_sage_id=10.1177_10781552231167812&rfr_iscdi=true |